Nothing Special   »   [go: up one dir, main page]

Lang et al., 2021 - Google Patents

First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes

Lang et al., 2021

View HTML
Document ID
8206008535484835283
Author
Lang D
Ritzberger L
Rambousek V
Horner A
Wass R
Akbari K
Kaiser B
Kronbichler J
Lamprecht B
Gabriel M
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Positron-emission tomography/computed tomography (PET/CT) is used for staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in patients treated with immune checkpoint inhibitor (ICI) therapy. Most available data in that …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01Social networking
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology

Similar Documents

Publication Publication Date Title
Hashimoto et al. Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer
Monaco et al. Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): a real world experience
Lang et al. First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes
Palumbo et al. Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: a multidisciplinary, machine learning-based approach
Bouron et al. Prognostic value of metabolic, volumetric and textural parameters of baseline [18F] FDG PET/CT in early triple-negative breast cancer
Zhou et al. 18F-FDG, 11C-methionine, and 68Ga-Pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features
Lee et al. Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma
Kim et al. Prognostic role of pre-treatment [18F] FDG PET/CT in patients with anaplastic thyroid cancer
Mendoza-Moreno et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer
Dumas et al. The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS)
Vivaldi et al. Early tumor shrinkage and depth of response evaluation in metastatic pancreatic cancer treated with first line chemotherapy: an observational retrospective cohort study
Laudicella et al. Preliminary findings of the role of FAPi in prostate cancer theranostics
Mataki et al. Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: A single-institution, retrospective analysis
Fosbøl et al. uPAR PET/CT for prognostication and response assessment in patients with metastatic castration-resistant prostate cancer undergoing radium-223 therapy: A prospective phase II study
Agostinetto et al. Post-neoadjuvant treatment strategies for patients with early breast cancer
Shin et al. The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy
Lee et al. Prognostic impact of total lesion glycolysis (TLG) from preoperative 18F-FDG PET/CT in stage II/III colorectal adenocarcinoma: extending the value of PET/CT for resectable disease
Lee et al. Muscle characteristics obtained using computed tomography as prognosticators in patients with castration-resistant prostate cancer
Rogé et al. Different prognostic values of tumour and nodal response to neoadjuvant chemotherapy depending on subtypes of inflammatory breast cancer, a 317 patient-study
Park et al. Relationship between systemic inflammatory markers, GLUT1 expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-small Cell Lung Carcinoma and their prognostic significance
Oriuchi et al. Monitoring of current cancer therapy by positron emission tomography and possible role of radiomics assessment
Sirico et al. Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer
Lee et al. Dual-time-point FDG uptake correlates with prognostic factors of invasive breast cancer: Clinical usefulness of early delayed scanning
Kang et al. Complete and durable response to nivolumab in recurrent poorly differentiated pancreatic neuroendocrine carcinoma with high tumor mutational burden
Nakane et al. Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence